Rare Brain Blood Vessel Disease Carries Higher Risks in Females
Article ID: 593374
Released: 10-Sep-2012 10:00 AM EDT
Source Newsroom: Wolters Kluwer Health: Lippincott Williams and Wilkins
Study in Neurosurgery Looks at Sex Differences in Moyamoya Disease
Newswise — Philadelphia, Pa. (September 10, 2012) – Women and girls are at increased risk of adverse outcomes after surgical treatment for moyamoya disease, an uncommon but serious disease of the brain blood vessels, reports a study in the September issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
Although the postoperative risks are increased, patients of both sexes with moyamoya disease achieve significant improvement after surgery. The study was performed by Dr. Gary K. Steinberg and colleagues of Stanford University.
Higher Rates and Risks of Moyamoya in Women and GirlsThe researchers analyzed the characteristics and outcomes of 430 patients undergoing surgical treatment (revascularization) for moyamoya disease between 1991 and 2010. All procedures were performed at Stanford by Dr. Steinberg.
Moyamoya disease is an uncommon condition in which arteries at the base of the brain become blocked. The disease gets its unusual name from Japanese for "puff of smoke," which describes the common appearance of the vessels on x-rays. The cause is unknown, but genetic factors may be involved.
Moyamoya disease occurs most often in children and young adults. Although it is more common in females, the new study is one of the first to evaluate possible sex-related differences in patient characteristics and outcomes after treatment.
Consistent with previous studies, there were more female patients than males: more than 70 percent of the patients were women and girls. The mean age was 31 years, with children accounting for about one-third of the patients. Treatment required a total of 717 revascularization procedures, as most patients had arterial blockage on both sides of the brain. This type of "bilateral" disease was more common in females.
Females were more than twice as likely to have transient ischemic attacks (TIAs)—sometimes called "mini-strokes"—as a symptom of moyamoya disease before surgery. However, there was no sex-related difference in the rate of more serious strokes.
After surgical revascularization, both male and female patients had significant improvements in health and functioning after surgery, with similar outcomes between the sexes. However, over five years after successful surgery, women and girls were about twice as likely to experience some type of adverse event, including stroke or death: 11.4 versus 5.3 percent.
The new study is the largest series of patients treated for moyamoya disease in North America. "These data suggest that sex may play an underappreciated role in influencing the natural history and posttreatment course in patients with moyamoya disease," the researchers write. Their findings suggest that moyamoya disease may have a "more aggressive nature" in women.
Nevertheless, Dr. Steinberg and coauthors emphasize that most patients—women as well as men—have excellent results after revascularization for moyamoya disease. Although adverse outcomes are more common in females, the overall risk of further problems is relatively low. The researchers call for further study to understand "the role of sex-specific influences on the pathophysiology of moyamoya disease."
About NeurosurgeryNeurosurgery, the Official Journal of the Congress of Neurological Surgeons, is your most complete window to the contemporary field of neurosurgery. Members of the Congress and non-member subscribers receive 3,000 pages per year packed with the very latest science, technology, and medicine, not to mention full-text online access to the world's most complete, up-to-the-minute neurosurgery resource. For professionals aware of the rapid pace of developments in the field, Neurosurgery is nothing short of indispensable.
About Lippincott Williams & Wilkins Lippincott Williams & Wilkins (LWW) is a leading international publisher of trusted content delivered in innovative ways to practitioners, professionals and students to learn new skills, stay current on their practice, and make important decisions to improve patient care and clinical outcomes. LWW is part of Wolters Kluwer Health, a leading global provider of information, business intelligence and point-of-care solutions for the healthcare industry. Wolters Kluwer Health is part of Wolters Kluwer, a market-leading global information services company with 2011 annual revenues of €3.4 billion ($4.7 billion).
About Lippincott Williams & Wilkins